PALI
Price
$1.86
Change
-$0.04 (-2.11%)
Updated
Dec 18, 10:45 AM (EDT)
RNAC
Price
$17.36
Change
-$0.95 (-5.19%)
Updated
Dec 18, 10:52 AM (EDT)
Ad is loading...

PALI vs RNAC

Header iconPALI vs RNAC Comparison
Open Charts PALI vs RNACBanner chart's image
Palisade Bio
Price$1.86
Change-$0.04 (-2.11%)
Volume$1.66K
CapitalizationN/A
Cartesian Therapeutics
Price$17.36
Change-$0.95 (-5.19%)
Volume$617
CapitalizationN/A
PALI vs RNAC Comparison Chart
Loading...
PALI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PALI vs. RNAC commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PALI is a Hold and RNAC is a Hold.

COMPARISON
Comparison
Dec 18, 2024
Stock price -- (PALI: $1.90 vs. RNAC: $18.31)
Brand notoriety: PALI and RNAC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PALI: 39% vs. RNAC: 126%
Market capitalization -- PALI: $3.26M vs. RNAC: $465.35M
PALI [@Biotechnology] is valued at $3.26M. RNAC’s [@Biotechnology] market capitalization is $465.35M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PALI’s FA Score shows that 1 FA rating(s) are green whileRNAC’s FA Score has 0 green FA rating(s).

  • PALI’s FA Score: 1 green, 4 red.
  • RNAC’s FA Score: 0 green, 5 red.
According to our system of comparison, RNAC is a better buy in the long-term than PALI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PALI’s TA Score shows that 5 TA indicator(s) are bullish while RNAC’s TA Score has 5 bullish TA indicator(s).

  • PALI’s TA Score: 5 bullish, 3 bearish.
  • RNAC’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, PALI is a better buy in the short-term than RNAC.

Price Growth

PALI (@Biotechnology) experienced а +31.94% price change this week, while RNAC (@Biotechnology) price change was -19.73% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.65%. For the same industry, the average monthly price growth was +1.45%, and the average quarterly price growth was +4.23%.

Reported Earning Dates

PALI is expected to report earnings on May 11, 2023.

RNAC is expected to report earnings on Aug 08, 2024.

Industries' Descriptions

@Biotechnology (-3.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RNAC($465M) has a higher market cap than PALI($3.26M). RNAC YTD gains are higher at: -11.469 vs. PALI (-78.531). PALI has higher annual earnings (EBITDA): -14.05M vs. RNAC (-262.89M). RNAC has more cash in the bank: 219M vs. PALI (8.04M). PALI has less debt than RNAC: PALI (357K) vs RNAC (14.7M). RNAC has higher revenues than PALI: RNAC (47.9M) vs PALI (0).
PALIRNACPALI / RNAC
Capitalization3.26M465M1%
EBITDA-14.05M-262.89M5%
Gain YTD-78.531-11.469685%
P/E Ratio0.02N/A-
Revenue047.9M-
Total Cash8.04M219M4%
Total Debt357K14.7M2%
FUNDAMENTALS RATINGS
PALI vs RNAC: Fundamental Ratings
PALI
RNAC
OUTLOOK RATING
1..100
9517
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
99
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
9553
P/E GROWTH RATING
1..100
10044
SEASONALITY SCORE
1..100
895

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PALI's Valuation (16) in the null industry is significantly better than the same rating for RNAC (99) in the Biotechnology industry. This means that PALI’s stock grew significantly faster than RNAC’s over the last 12 months.

PALI's Profit vs Risk Rating (100) in the null industry is in the same range as RNAC (100) in the Biotechnology industry. This means that PALI’s stock grew similarly to RNAC’s over the last 12 months.

PALI's SMR Rating (98) in the null industry is in the same range as RNAC (100) in the Biotechnology industry. This means that PALI’s stock grew similarly to RNAC’s over the last 12 months.

RNAC's Price Growth Rating (53) in the Biotechnology industry is somewhat better than the same rating for PALI (95) in the null industry. This means that RNAC’s stock grew somewhat faster than PALI’s over the last 12 months.

RNAC's P/E Growth Rating (44) in the Biotechnology industry is somewhat better than the same rating for PALI (100) in the null industry. This means that RNAC’s stock grew somewhat faster than PALI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PALIRNAC
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 13 days ago
84%
Declines
ODDS (%)
Bearish Trend 8 days ago
90%
Bearish Trend 6 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
PALI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RNAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYHEX36.820.01
+0.03%
Rydex Health Care A
MMFYX16.54N/A
N/A
MassMutual Equity Opports Svc
TEMVX8.03N/A
N/A
Nuveen Emerging Markets Eq W
SJGIX34.34N/A
N/A
Steward Large Cap Growth I
TRPSX26.90-0.15
-0.55%
Nuveen Large Cap Responsible Eq Prem

PALI and

Correlation & Price change

A.I.dvisor indicates that over the last year, PALI has been closely correlated with RNAC. These tickers have moved in lockstep 81% of the time. This A.I.-generated data suggests there is a high statistical probability that if PALI jumps, then RNAC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PALI
1D Price
Change %
PALI100%
+3.26%
RNAC - PALI
81%
Closely correlated
-2.71%
AGEN - PALI
81%
Closely correlated
+4.42%
NCNA - PALI
81%
Closely correlated
+1.19%
SNPX - PALI
81%
Closely correlated
-1.99%
ALLR - PALI
76%
Closely correlated
+15.18%
More

RNAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, RNAC has been closely correlated with SNPX. These tickers have moved in lockstep 91% of the time. This A.I.-generated data suggests there is a high statistical probability that if RNAC jumps, then SNPX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RNAC
1D Price
Change %
RNAC100%
-2.71%
SNPX - RNAC
91%
Closely correlated
-1.99%
ALLR - RNAC
86%
Closely correlated
+15.18%
NRXP - RNAC
86%
Closely correlated
+36.67%
PALI - RNAC
81%
Closely correlated
+3.26%
BTAI - RNAC
35%
Loosely correlated
-4.01%
More